Treatments for COVID-19 remain urgent and necessary despite increasing vaccine distribution. Studies suggest that monoclonal antibody (mAb) therapies prevent progression in early disease.1,2 In late 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for 2 mAb therapies, bamlanivimab and a combination of casirivimab and imdevimab, to treat COVID-19.3,4 However, previous mAb studies1,2 with a total of 852 participants (577 in one study1 and 275 in the other2) did not report a reduction in patient mortality, and only 5 participants across both trials (0.6%) were Native American. We present a retrospective quality improvement study on an early mAb treatment program for high-risk Native American patients at the Whiteriver Service Unit (WRSU), a rural acute care facility that serves as the primary hospital and public health department on the Fort Apache Indian Reservation in eastern Arizona.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: July 19, 2021.
Published: September 21, 2021. doi:10.1001/jamanetworkopen.2021.25866
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Close RM et al. JAMA Network Open.
Corresponding Author: Ryan M. Close, MD, MPH, Whiteriver Indian Hospital, Indian Health Service, 200 W Hospital Dr, PO Box 860, Whiteriver, AZ 85941 (email@example.com).
Author Contributions: Dr Close had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr Close and Mr Jones contributed equally to the work.
Concept and design: Close, Jones, McAuley.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Close, Jones, Jentoft.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Close, Jones.
Administrative, technical, or material support: All authors.
Supervision: Close, McAuley.
Conflict of Interest Disclosures: None reported.
Additional Contributions: We thank LCDR Trevor Thompson, PharmD, BCPS, Whiteriver Service Unit, for support in data collection and aggregation. LCDR Thompson did not receive any compensation.
You currently have no searches saved.
You currently have no courses saved.